Shares of NeuroPace Inc. (NPCE) are down over 60% from their 52-week high of $18.15, recorded in February of this year, and trade around $6.
NeuroPace is a medical device company that markets RNS System, an innovative therapy designed for adults suffering from drug-resistant focal epilepsy.
The RNS System is the first and only FDA-approved epilepsy neurostimulation device that can monitor and respond to brain activity. Similar to a pacemaker that monitors and responds to heart rhythms, the RNS System constantly monitors brainwaves, detects unusual activity that may lead to a seizure, and responds in real-time by sending brief pulses to disrupt this unusual activity.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.